Fox Run Management’s Protara Therapeutics TARA Stock Holding History

Fox Run Management’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-35,965	Closed	-$174K	–	1288
2026 Q1	$174K	Buy	+35,965	New	+$213K	0.03%	782

Other funds holding TARA

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Fox Run Management's TARA Position: Q2 2026 in Review

Fox Run Management sold out of Protara Therapeutics (TARA) in Q2 2026, closing a stake of 35,965 shares — an estimated $174K sold.

Fox Run Management first reported a position in TARA in Q1 2026 and held it in 1 quarter. The position peaked at $174K in Q1 2026. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

Fox Run Management reported no remaining Protara Therapeutics position as of Q2 2026 after selling out during the quarter.
Fox Run Management sold 35,965 Protara Therapeutics shares in Q2 2026, an estimated $174K.
Fox Run Management first reported a position in Protara Therapeutics in Q1 2026 and held it in 1 quarter.
Fox Run Management's Protara Therapeutics position peaked at $174K in Q1 2026.
120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.